The corporate office of Hep-Art is located in Amsterdam, the Netherlands. Its product-lead, the HepaRG-AMC-BAL, is protected by a patent application on the improved functionality of the HepaRG cell line cultured in the AMC-BAL. Research and development on the bio-artificial liver system was and is performed at the Academic Medical Center of the University of Amsterdam (AMC) by Dr. Robert Chamuleau MD, PhD and his research group. Hep-Art has obtained all exclusive rights to the patents protecting the HepaRG-AMC-BAL in the field of liver diseases.